Expert Picks

[ManicTrader]

PICKS WEEK. 3/15/2010. MEDIZONE INTL INC.(OTC BB: MZEI.OB)

STRICTLY TECHNICAL BUT SIMPLY LOVING THIS CHART SET UP!!
insert-text-here
insert-text-here

AsepticSure(TM) Eliminates All Pathogens

SAN FRANCISCO, March 8, 2010 /PRNewswire via COMTEX/ -- Medizone International, Inc. (OTC Bulletin Board: MZEI) announced today that it has successfully completed the first full round of room scale testing with its AsepticSure(TM) sterilization system. "Across the board," commented Dr Michael Shannon, "all pathogens of cause with HAIs were completely eliminated from stainless steel surfaces at concentrations well above 6 log. These results have confirmed the laboratory findings reported earlier this year, but what is of even greater significance are the insights gained into the technical modifications necessary to accommodate the unique requirements of decontaminating within a hospital environment."

Work will continue on the room scale testing program in order to expand our understanding of factors that will enhance the efficiency and effectiveness of AsepticSure(TM), particularly when dealing with contaminated textiles in time sensitive hospital spaces.

To meet the unique challenges of hospital acquired infections, Medizone has assembled an international team of professional engineers who are finalizing design of our first pre-manufacturing prototype to be used in hospital beta testing, which will commence later this spring. Medizone will build four highly instrumented prototype units for use in its hospital program, thereby enabling precise performance assessment of all AsepticSure(TM) systems as concurrent outcome measures, which will form the basis for final production design work, manufacturing and ultimately commercialization later this year.

Medizone International, Inc., is a research and development company engaged in developing its AsepticSure(TM) System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures. Current research is being conducted at Medizone's dedicated laboratories located in Innovation Park, Queen's University in Kingston, Ontario, Canada.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.


Investor Relations: 415-868-0300 / web site: www.medizoneint.com
E-mail: [e-mail]
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

AsepticSure(TM) Hospital Sterilization System Demonstrates Total Eradication of Super Bugs

SAN FRANCISCO, Feb. 4 /PRNewswire-FirstCall/ -- Medizone International, Inc. (OTC Bulletin Board: MZEI) announced today that every full scale test run completed thus far in its hospital room mock up facility has resulted in the total elimination of all bacteria present in the room. In this current phase of development, Medizone's scientific team will attempt to confirm, in a more realistic hospital setting, recent laboratory findings indicating extremely high antibacterial efficacy for its novel technology (6-7.2 log reductions) against the primary causative agents of hospital acquired infections (HAIs), sometimes referred to as "Super Bugs".  Dr. Michael Shannon, Medizone's Director of Medical Affairs commented, "From the very onset, our new scaled up sterilization system performed magnificently. We have now completed multiple runs with very high concentrations of MRSA, VRE and E. coli samples that were distributed throughout the test room. In every instance, the AsepticSure� system produced greater than 6 log (99.9999%) reductions, which by definition, is sterilization. It is noteworthy in this regard that there was absolutely no growth on any of the artificially contaminated surfaces exposed to the AsepticSure� process." Shannon continued, "Our intention now is to systematically collect empirically verifiable scientific data on all the remaining causative agents of HAIs. Given these recent results in a full room test setting which precisely mirrors our laboratory set up, we fully expect the same results with all remaining bacteria as well as Bacillus subtilis, the recognized surrogate for Anthrax. Thus, while more testing and data acquisition must be completed before moving into hospital beta testing, it now seems certain that AsepticSure� will deliver as promised."

Medizone's CEO Edwin Marshall added, "One of our concerns from the beginning has been the protection of the very expensive electronics found throughout hospitals. We have been testing electronic devices exposed to our process from the very beginning of our laboratory trials. While our electronic testing program will now be intensified to assure we are not making false assumptions, it is encouraging to note that one highly sensitive electronic instrument has now undergone over 50 exposures to our protocol, many at much higher O3 concentrations than we are now using, and it still performs as if it was brand new."

Medizone International, Inc., is a research and development company engaged in developing its AsepticSureâ?¢ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures. Â Current research is being conducted at Medizone's dedicated laboratories located in Innovation Park, Queen's University in Kingston, Ontario, Canada.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

Investor Relations: 415-868-0300 / web site: www.medizoneint.com

E-mail: [e-mail]